Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too

Chuikyo General Meeting on Aug. 23 Kowa took a pass on the reimbursement listing in August of its hoped-to-be big-seller hyperlipidemia drug Parmodia (pemafibrate) as it failed to reach an agreement with regulators on its pricing, a spokesperson said on...read more